asco 2023 oral presentation guidelines

Search form

Asco family of sites.

• ASCO Connection
• ASCO Daily News
• ASCO Journals
• ASCO Practice Central
• ASCO Education
• Cancer.Net - For Patients
• Conquer Cancer
• TAPUR Study
• The ASCO Post

ASCOconnection.org features blogs from members, the online version of the membership magazine, a discussion area, working groups, and links to the Membership Directory, Career Center, and Volunteer Portal.

ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members and oncology health care providers.

ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe.

ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care.

Stay updated on the latest oncology has to offer with ASCO Education—your online, on-demand resource for timely information, real-world application, and practice-changing care.

A cutting-edge health information technology platform, CancerLinQ® enables practitioners to learn from individual patients. By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care.

Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions.

Conquer Cancer, the ASCO Foundation, raises funds to support the world's leading researchers who are improving treatments and discovering cures for every cancer, every patient, everywhere.

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant.

The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and members.

Submission Guidelines & Requirements

Abstract eligibility & submission.

The ASCO Plenary Series is designed for quicker delivery of clinically relevant research. It highlights timely information for providers that includes context for clinical application provided by experts.

The abstract should address scientific questions, detail clinical observations, or contain primary scientific data in the form of a randomized phase II and III trial.

Submission Tracks

The ASCO Plenary Series will take place monthly through April and resume after the ASCO Annual Meeting. Mark your calendar for important key dates , including monthly abstract submission deadlines.

Submission Requirements

As you prepare your abstract submission, please make note of the following requirements.

• ASCO Account:  To submit an abstract, you will need to log in with an ASCO.org account. If you are not an ASCO member, you can create a guest account. The person submitting the abstract is not required to be an author on the abstract and will be able to select the first/presenting author on the designated step. However, the first author will need to accept/agree to all ASCO policies and will be held responsible for any violation of the policies. Submitters will be automatically assigned an abstract control number once they complete the Title step in the submitter.
• Identification of Original Research:  Indicate whether your abstract reports on original research. Original research means a systematic investigation designed for the purpose of expanding knowledge or understanding, including the analysis of data.
• Identification of Clinical Trials: Indicate whether your research is a clinical trial. A clinical trial is: a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes (National Institutes of Health [NIH] Office of Extramural Research.)
• Registration:  Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the first author will be asked to provide the name of the registry and the trial registration number during the abstract submission process. The clinical trial number will be included as part of the published abstract.
• Funding Source:  Indicate whether the abstract was funded by the NIH, a pharmaceutical or biotechnology company, a tobacco company, a foundation, or another source. The funding source will be included as part of the published abstract.
• Abstract Title: The title should objectively describe the study. Do not refer to study results or conclusions. ASCO reserves the right to edit conclusive titles.
• Coauthor(s):  Provide the full name, academic degree(s), institution, address, email address, and disclosure information for each author. You may list up to 20 individual authors for each abstract.
• Disclosure Declaration:  ASCO’s policy promotes balance, independence, objectivity, and scientific rigor in all of its activities through the disclosure of financial interests and other relationships, and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in ASCO’s Policy For Relationships With Companies  (Journal of Clinical Oncology 2017 35:7, 796-798). All authors are expected to disclose all relationships with for-profit health care companies.
• Distribute the  Coauthor Disclosure Form  to your coauthors, collect responses, and manually enter them at the COI Disclosure step. It is recommended to collect this information before starting your submission.
• Authors can submit their disclosure electronically through the  ASCO Disclosure Management System . If an author has provided his/her disclosure through the system already, the information will automatically populate across all of their submissions.
• Abstract Body/Table:  The body of your abstract should describe the background, methods, results, and conclusions of your research. You may type your abstract directly into the text box, cut and paste from an existing document, or upload a text file of your abstract. Do not exceed 2,600 characters (approximately 300 to 350 words) for the total of your abstract title and body including section titles, and table. The character count does not include spaces or author names or institutions. One data table is permitted per abstract. Limit your table to no more than 10 rows. Do not use shading or merge cells with centered text, as this formatting will not render in the published abstract. Illustrations and figures are not permitted.
• Submission Track:  Select the most appropriate track for the abstract. The ASCO Scientific Review Committee has the authority to recategorize an abstract.
• Submission Fee: A $60 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission.
• Abstract Changes : The designated submitter or the first author may view and modify abstracts any time between submission and the deadline. Your ASCO username and password are required to log in and edit the submission. Changes to accepted abstracts are permitted on a case-by-case basis. After publication, only corrections for major errors or omissions are considered and must be submitted by the first author.
• Withdrawal of Abstracts: If the first author wishes to withdraw the abstract from presentation after notifications have been sent by ASCO, the author must submit a written request within twenty-four (24) hours .

First Author Responsibilities

The First Author must:

• Agree to the Prior Presentation/Publication and Confidentiality Policies on behalf of all parties involved in the study
• ​Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
• Verify that all coauthors are aware of the contents of the abstract and support its data.
• Agree, on behalf of all coauthors, to transfer copyright to ASCO.
• Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journel Edits

706 people named Kyle got together in Kyle, but still no world record

Philippines blames China for loss of giant clams in disputed shoal

Victims of Vietnam, Iraq and Gaza - the follies of war

Ed Dwight, Black astronaut candidate, goes to space 60 years late

Antengene to present one oral and four abstracts at asco 2024.

• Oral Presentation a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer
• Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor (XPO1 Inhibitor)
• Journal Publication: the first-in-human Phase I dose-escalation study of ATG-017 (ERK1/2 inhibitor) in patients with advanced solid tumors

SHANGHAI and HONG KONG , May 24, 2024 /PRNewswire/ -- Antengene Corporation Limited ( " Antengene ",  SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced  one oral presentation, three poster presentations and a journal publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 st to June 4 th at the McCormick Place Convention Center in Chicago, IL , the United States .

Details of the Oral Presentation:

ATG-008 (mTORC1/2 Inhibitor)

Title:    A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

Abstract:   5509

Session: Clinical Science Symposium - Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum

Date: June 1, 2024

Time: 1:15 PM - 2:45 PM (Central Daylight Time)

           2: 15 AM - 3:45 AM , June 2, 2024 (Beijing Time)

• 31 checkpoint inhibitor (CPI)-nave cervical cancer patients who previously had at least one systemic line of chemotherapy were enrolled in the TORCH-2 study as of Oct 20 th 2023.
• ATG-008 (Onatasertib; oral TORC1/2 inhibitor) combined with toripalimab (anti-PD-1 antibody) showed promising anti-tumor activity and acceptable tolerability in cervical cancer patients, achieving an overall response rate (ORR) of 53.3% and a disease control rate of 86.7%.
• In general, ATG-008 in combination with toripalimab are very well tolerated. The most common grade 3 treatment-related adverse events (TRAEs) included rash (12.9%), decreased lymphocyte count (9.7%), and decreased platelet count (6.5%).
• Encouraging response rates and disease stabilization were observed in patients, regardless of PD-L1 expression, with further data being collected in an ongoing expansion cohort for CPI-treated cervical cancer.

Details of the Poster Presentations:

ATG-031 (anti-CD24 monoclonal antibody)

Title:    A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)

Abstract: TPS2691

Session : Developmental Therapeutics-Immunotherapy

Time: 9:00 AM - 12:00 PM (Central Daylight Time)

          10:00 PM , June 1 - 1:00 AM , June 2, 2024 (Beijing Time)

• ATG-031 is a first-in-class CD24 antibody that promotes cancer cell phagocytosis and T cell activity by disrupting the CD24-Siglec-10 interaction on macrophages, while also triggering antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
• The Phase I PERFORM study is designed to evaluate the safety and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma, employing a dose-escalation phase with a Bayesian Optimal Interval (BOIN) design and a dose-expansion phase with two or more dose levels to determine the recommended phase II dose (RP2D).
• As of April 2024 , the study is underway in 4 U.S. sites, and the first dose level has been cleared.

ATG-022 (Claudin 18.2 Antibody-drug Conjugate)

Title: An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH)

Abstract: 3032

Session: Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology

• ATG-022 is a Claudin 18.2 (CLDN 18.2)-targeting antibody-drug conjugate (ADC) with sub-nM high affinity that showed promising tumor inhibition activity in vitro and in vivo . The CLINCH Phase I trial is assessing its safety, tolerability, and efficacy in patients with advanced/metastatic solid tumors.
• As of October 9 th , 2023, 10 patients have been enrolled, receiving doses ranging from 0.3 to 2.4 mg/kg. The most common grade 3 TRAEs included nausea, vomiting, and decreased appetite, each occurring in 30% of patients. No dose-limiting toxicities (DLTs) were reported.
• Preliminary efficacy data among 7 gastric cancer patients across multiple doses in the Phase I dose escalation demonstrated one complete response (CR) in a patient with gastric cancer (2.4 mg/kg, CLDN 18.2-negative) and one partial response (PR) in another patient (1.8 mg/kg, CLDN 18.2 expression undetermined). ATG-022 demonstrated tolerability, safety, and potential anti-tumor activity. A Phase II trial is currently enrolling patients with gastric cancer and other solid tumors.

Selinexor (XPO1 Inhibitor)

Title:    Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose-escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)

Abstract:   7065

Session: Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia

Date: June 3, 2024

          10:00 PM , June 3 - 1:00 AM , June 4, 2024 (Beijing Time)

• The Phase I/II TOUCH study is investigating selinexor combined with different drugs in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL). Cohort C of the study aims to evaluate the safety, tolerability and preliminary efficacy of selinexor in combination with anti-PD-1 antibody tislelizumab.
• As of December 25 th , 2023, 12 patients were enrolled, with no DLTs observed, and the maximum tolerated dose (MTD) was not reached. The most common adverse events included asthenia, neutropenia, and nausea/vomiting. Grade 3 adverse events occurred in 58.3% of patients.
• The ORR was 72.7% among 11 efficacy evaluable patients, including a CR rate of 36.4%. The combination showed a tolerable safety profile and promising efficacy.

Details of the Journal Publication:

ATG-017 (ERK1/2 Inhibitor)

Title:    Results of a first-in-human, dose-escalation phase I study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors

Abstract:   e15114

Session: Publication Only: Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology

• ATG-017, an oral and selective ERK1/2 inhibitor, was evaluated in a Phase I study to assess safety, pharmacokinetics, and MTD in patients with refractory advanced solid tumors.
• At the 20 mg BID level, no DLTs were observed, and pharmacokinetic analysis revealed effective ERK inhibition at this dose. Common treatment-emergent adverse events (TEAEs) were consistent with previously reported toxicities with other ERK pathway inhibitors (gastrointestinal, skin, and ocular adverse events).
• Efficacy data showed that one patient (4.8%) achieved a PR, while 8 patients (38%) achieved stable disease (SD).

About Antengene

Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders" .

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia , and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO (selinexor) already approved in Mainland of China , Taiwan China, Hong Kong China , Macau China, South Korea , Singapore and Australia .

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023 , and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts:  Donald Lung E-mail: [email protected]   Mobile: +86 18420672158

PR Contacts: Peter Qian E-mail: [email protected]   Mobile: +86 13062747000

PR Newswire 24th May 2024, 10:30 GMT+10

Read This Next

Big News Network

• Big News Network News Agency
• Midwest Radio Network
• Mainstream Media

BIG NEWS NETWORK.COM

• Contact & Support
• Terms & Conditions

PRODUCTS & SERVICES

• News Releases

Copyright © 1998-2024 Big News Network All rights reserved. ISSN : 2616-6917

• Download PDF
• Share X Facebook Email LinkedIn
• Permissions

A Patient With Slow Communication and Difficulty Walking

• 1 Department of Surgery, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan

A 70-year-old woman with hypertension and dyslipidemia presented with slow communication and difficulty walking 90 days after 6 courses of postoperative chemotherapy (docetaxel plus cyclophosphamide) following right breast cancer surgery (pT2N2aM0, stage IIIA). She had been hospitalized for anorexia 1 week before, had good oral intake after admission, and was discharged the day prior. After the third course of postoperative chemotherapy, she experienced severe nausea, leading to poor food intake and 28% loss of body weight over the following 6 months. She did not consume alcohol or illegal drugs. At presentation, she was fever free with a blood pressure of 102/64 mm Hg, was expressionless and disoriented, and had delayed responses, which made the accurate assessment of memory impairment difficult. Aphasia was not observed. She was able to follow her gaze but had nystagmus during the left gaze. She could not move her upper and lower extremities smoothly and had an ataxic gait. Results of a manual muscle test were normal. No stiff neck or involuntary movements were observed. Physical examination revealed no signs of meningeal irritation. Blood test results showed a white blood cell count of 14 580/μL (to convert to ×10 9 /L, multiply by 0.001), C-reactive protein of 7.81 mg/dL (to convert to mg/L, multiply by 10), sodium of 129 mEq/L (to convert to mmol/L, multiply by 1), potassium of 3.4 mEq/L (to convert to mmol/L, multiply by 1), calcium of 8.9 mg/dL (to convert to mmol/L, multiply by 0.25), inorganic phosphorus of 4.0 mg/dL (to convert to mmol/L, multiply by 0.323), and magnesium of 1.4 mg/dL (to convert to mmol/L, multiply by 0.4114). Creatinine level and liver, thyroid, and adrenal function were normal. Urinalysis suggested a urinary tract infection. Magnetic resonance imaging (MRI) was performed ( Figure ).

Read More About

Matsushima H , Kikuchi M , Shintani T. A Patient With Slow Communication and Difficulty Walking. JAMA Oncol. Published online May 23, 2024. doi:10.1001/jamaoncol.2024.0978

Manage citations:

© 2024

Artificial Intelligence Resource Center

Oncology in JAMA : Read the Latest

Browse and subscribe to JAMA Network podcasts!

Others Also Liked

Select your interests.

Customize your JAMA Network experience by selecting one or more topics from the list below.

• Academic Medicine
• Acid Base, Electrolytes, Fluids
• Allergy and Clinical Immunology
• American Indian or Alaska Natives
• Anesthesiology
• Anticoagulation
• Art and Images in Psychiatry
• Artificial Intelligence
• Assisted Reproduction
• Bleeding and Transfusion
• Caring for the Critically Ill Patient
• Challenges in Clinical Electrocardiography
• Climate and Health
• Climate Change
• Clinical Challenge
• Clinical Decision Support
• Clinical Implications of Basic Neuroscience
• Clinical Pharmacy and Pharmacology
• Complementary and Alternative Medicine
• Consensus Statements
• Coronavirus (COVID-19)
• Critical Care Medicine
• Cultural Competency
• Dental Medicine
• Dermatology
• Diabetes and Endocrinology
• Diagnostic Test Interpretation
• Drug Development
• Electronic Health Records
• Emergency Medicine
• End of Life, Hospice, Palliative Care
• Environmental Health
• Equity, Diversity, and Inclusion
• Facial Plastic Surgery
• Gastroenterology and Hepatology
• Genetics and Genomics
• Genomics and Precision Health
• Global Health
• Guide to Statistics and Methods
• Hair Disorders
• Health Care Delivery Models
• Health Care Economics, Insurance, Payment
• Health Care Quality
• Health Care Reform
• Health Care Safety
• Health Care Workforce
• Health Disparities
• Health Inequities
• Health Policy
• Health Systems Science
• History of Medicine
• Hypertension
• Images in Neurology
• Implementation Science
• Infectious Diseases
• Innovations in Health Care Delivery
• JAMA Infographic
• Law and Medicine
• Leading Change
• Less is More
• LGBTQIA Medicine
• Lifestyle Behaviors
• Medical Coding
• Medical Devices and Equipment
• Medical Education
• Medical Education and Training
• Medical Journals and Publishing
• Mobile Health and Telemedicine
• Narrative Medicine
• Neuroscience and Psychiatry
• Notable Notes
• Nutrition, Obesity, Exercise
• Obstetrics and Gynecology
• Occupational Health
• Ophthalmology
• Orthopedics
• Otolaryngology
• Pain Medicine
• Palliative Care
• Pathology and Laboratory Medicine
• Patient Care
• Patient Information
• Performance Improvement
• Performance Measures
• Perioperative Care and Consultation
• Pharmacoeconomics
• Pharmacoepidemiology
• Pharmacogenetics
• Pharmacy and Clinical Pharmacology
• Physical Medicine and Rehabilitation
• Physical Therapy
• Physician Leadership
• Population Health
• Primary Care
• Professional Well-being
• Professionalism
• Psychiatry and Behavioral Health
• Public Health
• Pulmonary Medicine
• Regulatory Agencies
• Reproductive Health
• Research, Methods, Statistics
• Resuscitation
• Rheumatology
• Risk Management
• Scientific Discovery and the Future of Medicine
• Shared Decision Making and Communication
• Sleep Medicine
• Sports Medicine
• Stem Cell Transplantation
• Substance Use and Addiction Medicine
• Surgical Innovation
• Surgical Pearls
• Teachable Moment
• Technology and Finance
• The Art of JAMA
• The Arts and Medicine
• The Rational Clinical Examination
• Tobacco and e-Cigarettes
• Translational Medicine
• Trauma and Injury
• Treatment Adherence
• Ultrasonography
• Users' Guide to the Medical Literature
• Vaccination
• Venous Thromboembolism
• Veterans Health
• Women's Health
• Workflow and Process
• Wound Care, Infection, Healing
• Register for email alerts with links to free full-text articles
• Access PDFs of free articles
• Manage your interests
• Save searches and receive search alerts

• Skip to content
• Skip to navigation
• Skip to footer

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

Back-to-back plenary presentations for laura and adriatic phase iii trials reinforce the potential of tagrisso and imfinzi in early lung cancer settings, destiny-breast06 data underscore potential of enhertu earlier in hr-positive, her2-low breast cancer treatment, and in a broader population including her2-ultralow  .

AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 31 May to 4 June 2024.

More than 100 abstracts will feature 25 approved and potential new medicines across the Company’s diverse oncology portfolio and pipeline, including two late-breaking plenary presentations, a special late-breaking abstract session presentation and 15 oral presentations. Highlights include:

• LAURA Phase III trial of Tagrisso (osimertinib) in unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) (Plenary LBA4).
• ADRIATIC Phase III trial of Imfinzi (durvalumab) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent CRT (cCRT) (Plenary LBA5).
• DESTINY-Breast06 Phase III trial of Enhertu (trastuzumab deruxtecan) in patients with metastatic hormone receptor (HR)-positive HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy (LBA1000).
• First-in-human, investigator-initiated trial of C-CAR031, a novel autologous armoured Glypican 3 (GPC3) targeting chimeric antigen receptor T cell (CAR-T) therapy, in patients with liver cancer. The CAR-T is based on AZD5851, a novel cell therapy designed by AstraZeneca (Rapid Oral Abstract 4019).
• Two late-breaking presentations from the externally sponsored I-SPY2.2 Phase II trial of neoadjuvant datopotamab deruxtecan (Dato-DXd), alone and in combination with Imfinzi , in patients with breast cancer (LBA501 and LBA509).

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “Our plenary data at ASCO show the pioneering role of our medicines in curative-intent lung cancer treatment and highlight progress toward our continued ambition to have a medicine for more than half of all patients treated for lung cancer by 2030. The overwhelming efficacy in the LAURA trial will add to the extensive body of evidence for Tagrisso in EGFR-mutated non-small cell lung cancer, and the impressive survival data from ADRIATIC will show the potential of Imfinzi to transform outcomes in limited-stage small cell lung cancer.”

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Data from our antibody drug conjugates at ASCO underscore the opportunity to replace traditional chemotherapy with these medicines for many patients as we expand their use to new populations. DESTINY-Breast06 results will demonstrate the potential to treat patients across a broader spectrum of HR-positive metastatic breast cancer with Enhertu , including those with HER2-ultralow expression who have never had access to HER2-directed therapy before. We're also excited by the I-SPY2.2 efficacy and tolerability data for datopotamab deruxtecan plus Imfinzi , which will show the potential of combining antibody drug conjugates with immunotherapy in the early-stage setting.”

Transforming treatment expectations across earlier-stage lung cancer settings

Several presentations will reinforce the Company’s progress toward moving lung cancer treatment to earlier stages of disease. These include:

• A late-breaking plenary presentation showcasing progression-free survival (PFS) results from the LAURA Phase III trial evaluating Tagrisso in unresectable, Stage III EGFRm NSCLC after CRT. In February , high-level results showed a statistically significant and highly clinically meaningful PFS benefit for Tagrisso in this setting.
• A late-breaking plenary presentation highlighting overall survival (OS) and PFS results from the ADRIATIC Phase III trial of Imfinzi in patients with LS-SCLC who had not progressed following cCRT. In April , high-level results from an interim analysis showed a statistically significant and clinically meaningful OS and PFS benefit for Imfinzi in this setting.
• An oral presentation of an analysis from the ADAURA Phase III trial of Tagrisso in the adjuvant treatment of early-stage (IB, II and IIIA) EGFRm NSCLC, assessing the potential for circulating tumour DNA-based molecular residual disease to predict disease recurrence.
• A rapid oral presentation of an exploratory analysis from the AEGEAN Phase III trial of Imfinzi -based treatment before and after surgery in patients with resectable early-stage (IIA-IIIB) NSCLC, evaluating efficacy in patients with N2 disease (cancer in the lymph nodes on the same side as the affected lung or between the lungs).
• A poster presentation of updated OS, PFS and safety results from the COAST Phase II trial of Imfinzi  in combination with novel immunotherapies oleclumab, an anti-CD73 monoclonal antibody, and monalizumab, an anti-NKG2A monoclonal antibody, in unresectable, Stage III NSCLC, supporting the PACIFIC-9 Phase III trial in this patient population.

In metastatic lung cancer, the Company will present data that underscore its commitment to extending the benefits of antibody drug conjugates (ADCs) to more patients. A poster presentation will share updated safety and efficacy results, including by PD-L1 expression, from the TROPION-Lung02 Phase Ib trial of datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy as 1st-line treatment for patients with advanced NSCLC without actionable genomic alterations. These data build on previously presented results from the TROPION-Lung01 Phase III trial demonstrating the potential of this novel ADC in advanced disease. Datopotamab deruxtecan in combination with immunotherapies is being further explored in multiple Phase III trials in this setting, including AVANZAR, TROPION-Lung07 and TROPION-Lung08.

Redefining the breast cancer treatment landscape with ADCs across subtypes and stages of disease

A late-breaking presentation will showcase efficacy and safety outcomes from the DESTINY-Breast06 Phase III trial. In April , high-level results showed Enhertu demonstrated a statistically significant and clinically meaningful improvement in PFS versus standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer. A clinically meaningful PFS improvement was also seen in patients with HER2-ultralow expression.

An oral presentation will spotlight data from an interim analysis of the dose-expansion phase of the DESTINY-Breast07 Phase Ib/II trial assessing Enhertu alone or in combination with pertuzumab as 1st-line treatment in HER2-positive metastatic breast cancer. These regimens are being further explored in the DESTINY-Breast09 Phase III clinical trial.

Additionally, a poster presentation will share updated OS and PFS results from the DESTINY-Breast03 Phase III trial of Enhertu versus trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

An oral presentation will feature patient-reported outcomes data from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan in patients with inoperable or metastatic HR-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. Previously presented primary results from TROPION-Breast01 showed datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in PFS versus investigator’s choice of chemotherapy.

Two late-breaking presentations of results from the externally sponsored I-SPY2.2 Phase II trial will highlight the rates of pathologic complete response associated with neoadjuvant datopotamab deruxtecan, alone and in combination with Imfinzi , across breast cancer subtypes.

Advancing the next wave of medicines and combination therapies to attack cancer from multiple angles

A rapid oral presentation will spotlight safety and preliminary efficacy results from an investigator-initiated trial of C-CAR031, a novel autologous armoured Glypican 3 (GPC3) targeting chimeric antigen receptor T cell (CAR-T) therapy that is being investigated for hepatocellular carcinoma. The CAR-T is based on AZD5851, a novel cell therapy designed by AstraZeneca using their transforming growth factor-beta receptor II (TGFβRII) dominant negative armouring platform and is manufactured by AbelZeta Pharmaceuticals Inc. C-CAR031 is being developed in China under a co-development agreement between AbelZeta and AstraZeneca. AstraZeneca’s TGFβRII dominant negative armouring is designed to resist the immuno-suppressive tumour microenvironment and enhance the potential effectiveness of CAR-Ts in solid tumours.

A rapid abstract update will feature updated efficacy data from a Phase I trial of AZD0901, a potential first-in-class ADC targeting Claudin 18.2, which has shown promise as a therapeutic target in gastric cancer. First results were presented at the ASCO Plenary Series 2023.

Additionally, a clinical science symposium presentation of the externally sponsored CAPRI Phase II trial will share efficacy and safety results for ceralasertib, an ataxia telangiectasia and rad3-related (ATR) kinase inhibitor, plus Lynparza (olaparib) in patients with platinum-sensitive recurrent high-grade serous ovarian cancer.

Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with Daiichi Sankyo Company Limited to develop and commercialise Enhertu and datopotamab deruxtecan, and with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza. AstraZeneca obtained full oncology rights to monalizumab from Innate Pharma in October 2018 through a co-development and commercialisation agreement initiated in 2015.

Key AstraZeneca presentations during ASCO 2024

AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca .

Contacts For details on how to contact the Investor Relations Team, please click here . For media contacts, click here .

• Corporate and financial

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes.

A .gov website belongs to an official government organization in the United States.

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

• Guidelines and Guidance Library
• Core Practices
• Isolation Precautions Guideline
• Disinfection and Sterilization Guideline
• Environmental Infection Control Guidelines
• Hand Hygiene Guidelines
• Multidrug-resistant Organisms (MDRO) Management Guidelines
• Catheter-Associated Urinary Tract Infections (CAUTI) Prevention Guideline
• Tools and resources
• Evaluating Environmental Cleaning

Infection Control Basics

• Infection control prevents or stops the spread of infections in healthcare settings.
• Healthcare workers can reduce the risk of healthcare-associated infections and protect themselves, patients and visitors by following CDC guidelines.

Germs are a part of everyday life. Germs live in our air, soil, water and in and on our bodies. Some germs are helpful, others are harmful.

An infection occurs when germs enter the body, increase in number and the body reacts. Only a small portion of germs can cause infection.

Terms to know

• Sources : places where infectious agents (germs) live (e.g., sinks, surfaces, human skin). Sources are also called reservoirs.
• Susceptible person: someone who is not vaccinated or otherwise immune. For example, a person with a weakened immune system who has a way for the germs to enter the body.
• Transmission: a way germs move to the susceptible person. Germs depend on people, the environment and/or medical equipment to move in healthcare settings. Transmission is also called a pathway.
• Colonization: when someone has germs on or in their body but does not have symptoms of an infection. Colonized people can still transmit the germs they carry.

For an infection to occur, germs must transmit to a person from a source, enter their body, invade tissues, multiply and cause a reaction.

How it works in healthcare settings

Sources can be:.

• People such as patients, healthcare workers and visitors.
• Dry surfaces in patient care areas such as bed rails, medical equipment, countertops and tables).
• Wet surfaces, moist environments and biofilms (collections of microorganisms that stick to each other and surfaces in moist environments, like the insides of pipes).
• Cooling towers, faucets and sinks, and equipment such as ventilators.
• Indwelling medical devices such as catheters and IV lines.
• Dust or decaying debris such as construction dust or wet materials from water leaks.

Transmission can happen through activities such as:

• Physical contact, like when a healthcare provider touches medical equipment that has germs on it and then touches a patient before cleaning their hands.
• Sprays and splashes when an infected person coughs or sneezes. This creates droplets containing the germs, and the droplets land on a person's eyes, nose or mouth.
• Inhalation when infected patients cough or talk, or construction zones kick up dirt and dust containing germs, which another person breathes in.
• Sharps injuries such as when someone is accidentally stuck with a used needle.

A person can become more susceptible to infection when:

• They have underlying medical conditions such as diabetes, cancer or organ transplantation. These can decrease the immune system's ability to fight infection.
• They take medications such as antibiotics, steroids and certain cancer fighting medications. These can decrease the body's ability to fight infection.
• They receive treatments or procedures such as urinary catheters, tubes and surgery, which can provide additional ways for germs to enter the body.

Recommendations

Healthcare providers.

Healthcare providers can perform basic infection prevention measures to prevent infection.

There are 2 tiers of recommended precautions to prevent the spread of infections in healthcare settings:

• Standard Precautions , used for all patient care.
• Transmission-based Precautions , used for patients who may be infected or colonized with certain germs.

There are also transmission- and germ-specific guidelines providers can follow to prevent transmission and healthcare-associated infections from happening.

Learn more about how to protect yourself from infections in healthcare settings.

For healthcare providers and settings

• Project Firstline : infection control education for all frontline healthcare workers.
• Infection prevention, control and response resources for outbreak investigations, the infection control assessment and response (ICAR) tool and more.
• Infection control specifically for surfaces and water management programs in healthcare settings.
• Preventing multi-drug resistant organisms (MDROs).

Infection Control

CDC provides information on infection control and clinical safety to help reduce the risk of infections among healthcare workers, patients, and visitors.

For Everyone

Health care providers, public health.